Research on dyslipidaemias in 2017 reaffirmed the central role of reducing the levels of atherogenic apolipoprotein B-containing lipoproteins, predominantly LDL, in preventing ischaemic cardiovascular events. However, whether increasing HDL-cholesterol levels in isolation can reduce cardiovascular risk remains to be determined.
Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets / A.L. Catapano. - In: NATURE REVIEWS. CARDIOLOGY. - ISSN 1759-5002. - 15:2(2018 Feb), pp. 75-76. [10.1038/nrcardio.2017.221]
Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets
A.L. Catapano
2018
Abstract
Research on dyslipidaemias in 2017 reaffirmed the central role of reducing the levels of atherogenic apolipoprotein B-containing lipoproteins, predominantly LDL, in preventing ischaemic cardiovascular events. However, whether increasing HDL-cholesterol levels in isolation can reduce cardiovascular risk remains to be determined.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2018-Nat Rev Cardiol-Submitted.pdf
accesso riservato
Tipologia:
Pre-print (manoscritto inviato all'editore)
Dimensione
899.16 kB
Formato
Adobe PDF
|
899.16 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
